Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial
Mansour A, Mohajeri-Tehrani MR, Samadi M, Qorbani M, Merat S, Adibi H, Poustchi H, Hekmatdoost A
Nutrition journal · 73 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- National Nutrition and Food Technology Research Institute
- Gobierno
- National Institute for Medical Research Developments
Según 2 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2021-04-10 · Nutr J · vol. 20 · número 1 · pág. 35
- Editorial
- BioMed Central
- Citado
- 96 citas · más que el 99% de estudios similares · 7.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 52 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Coffee research and impacts · Liver Disease Diagnosis and Treatment · Alcohol Consumption and Health Effects
- Palabras clave
- non-alcoholic fatty liver disease, type 2 diabetes, caffeine, chlorogenic acid, hepatic steatosis, liver stiffness, insulin resistance, inflammation, liver enzymes, cytokeratin 18, lipid profile
- MeSH
- liver, humans, diabetes mellitus, type 2, insulin resistance, chlorogenic acid, caffeine, double-blind method, coffee, dietary supplements, non-alcoholic fatty liver disease
8 autores
- Asieh Mansour🇮🇷National Nutrition and Food Technology Research Institute; Shahid Beheshti University of Medical Sciences
- Mohammad Reza Mohajeri‐Tehrani🇮🇷Endocrinology and Metabolism Clinical Sciences Institute; Tehran University of Medical Sciences
- Majid Samadi🇮🇷Shariati Hospital; Tehran University of Medical Sciences
- Mostafa Qorbani🇮🇷Alborz University of Medical Sciences; Endocrinology and Metabolism Population Sciences Institute; Tehran University of Medical Sciences
- Shahin Merat🇮🇷Digestive Disease Research Institute; Tehran University of Medical Sciences
- Hossein Adibi🇮🇷Endocrinology and Metabolism Clinical Sciences Institute; Diabetes Research Center; Tehran University of Medical Sciences
- Hossein Poustchi🇮🇷Digestive Disease Research Institute; Tehran University of Medical Sciences
- Azita Hekmatdoost🇮🇷 · autor de correspondenciaNational Nutrition and Food Technology Research Institute; Shahid Beheshti University; Shahid Beheshti University of Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Non-alcoholic fatty liver disease (NAFLD) is much more frequent and more severe, including cirrhosis, hepatocellular carcinoma in patients with type 2 diabetes. Coffee is a complex beverage with hundreds of compounds whereas caffeine and chlorogenic acid are the most abundant bioactive compounds. The published epidemiological data demonstrating beneficial associations between all categories of coffee exposure and ranges of liver outcomes are rapidly growing; however, the main contributors and cause-effect relationships have not yet been elucidated. To address existing knowledge gaps, we sought to determine the efficacy and safety of 6 months chlorogenic acid and/or caffeine supplementation in patients with type 2 diabetes affected by NAFLD.
Methods
This trial was carried out at two Diabetes Centers to assess the effects of supplementation with daily doses of 200 mg chlorogenic acid, 200 mg caffeine, 200 mg chlorogenic acid plus 200 mg caffeine or placebo (starch) in patients with type 2 diabetes and NAFLD. The primary endpoint was reduction of hepatic fat and stiffness measured by FibroScan, and changes in serum hepatic enzymes and cytokeratin - 18 (CK-18) levels. Secondary endpoints were improvements in metabolic (including fasting glucose, homeostasis model assessment-estimated insulin resistance (HOMA-IR), hemoglobin A1c (HBA1C), C-peptide, insulin and lipid profiles) and inflammatory (including nuclear factor k-B (NF-KB), tumor necrosis factor (TNF-α), high sensitive- C reactive protein(hs-CRP)) parameters from baseline to the end of treatment.
Results
Neither chlorogenic acid nor caffeine was superior to placebo in attenuation of the hepatic fat and stiffness and other hepatic outcomes in patients with diabetes and NAFLD. Except for the lower level of total cholesterol in caffeine group (p = 0.04), and higher level of insulin in chlorogenic acid plus caffeine group (p = 0.01) compared with placebo, there were no significant differences among the treatment groups.
Conclusion
These findings do not recommend caffeine and/or chlorogenic acid to treat NAFLD in type 2 diabetes patients.
Trial registration
IRCT201707024010N21 . Registered 14 September 2017.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.